Lytix Biopharma AS
OSE:LYTIX
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| NO |
L
|
Lytix Biopharma AS
OSE:LYTIX
|
652.6m NOK |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
397.7B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.8B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.6B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.7B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.5B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -3 055 100% |
| 30th Percentile | -3.7% |
| Median | 1.8% |
| 70th Percentile | 6.8% |
| Max | 784.1% |
Other Profitability Ratios
Lytix Biopharma AS
Glance View
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Lytix Biopharma AS is -12 206.9%, which is below its 3-year median of -4 334%.
Over the last 3 years, Lytix Biopharma AS’s Operating Margin has decreased from -4 132.4% to -12 206.9%. During this period, it reached a low of -14 977.1% on Mar 31, 2025 and a high of -545.9% on Jun 30, 2024.
